To evaluate the treatment of advanced islet-cell carcinoma, we randomly assigned 84 patients to streptozocin alone or streptozocin plus fluorouracil. Each regimen was given in five-day courses. The most frequent toxic effects were nausea and vomiting, mild and reversible renal toxicity, and bone-marrow depression with the combination regimen. The combination had advantages over streptozocin alone in overall rate of response (63 vs. 36 per cent) and in rates of complete response (33 vs. 12 per cent). There was no evidence of a preferential response among types of functional tumors. Objective responses were generally of long duration (median, 17 months) and of substantive clinical benefit. Treatment with the combination also yielded a survival advantage over treatment with streptozocin alone (medians, 26 and 16 1/2 months), but this difference is not statistically significant. In spite of gastrointestinal side effects, streptozocin combined with fluorouracil appears to be a valuable treatment for advanced islet-cell carcinoma.
This article has been cited by other articles:
Vilar, E., Salazar, R., Perez-Garcia, J., Cortes, J., Oberg, K., Tabernero, J.
(2007). Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors. Endocr Relat Cancer
14: 221-232
[Abstract][Full Text]
Butturini, G, Bettini, R, Missiaglia, E, Mantovani, W, Dalai, I, Capelli, P, Ferdeghini, M, Pederzoli, P, Scarpa, A, Falconi, M
(2006). Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer
13: 1213-1221
[Abstract][Full Text]
Kwekkeboom, D. J., Teunissen, J. J., Bakker, W. H., Kooij, P. P., de Herder, W. W., Feelders, R. A., van Eijck, C. H., Esser, J.-P., Kam, B. L., Krenning, E. P.
(2005). Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic Tumors. JCO
23: 2754-2762
[Abstract][Full Text]
Kouvaraki, M. A., Ajani, J. A., Hoff, P., Wolff, R., Evans, D. B., Lozano, R., Yao, J. C.
(2004). Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients With Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas. JCO
22: 4762-4771
[Abstract][Full Text]
Kaltsas, G. A., Besser, G. M., Grossman, A. B.
(2004). The Diagnosis and Medical Management of Advanced Neuroendocrine Tumors. Endocr. Rev.
25: 458-511
[Abstract][Full Text]
Pathak, R. D., Tran, T. H., Burshell, A. L.
(2004). A Case of Dopamine Agonists Inhibiting Pancreatic Polypeptide Secretion from an Islet Cell Tumor. J. Clin. Endocrinol. Metab.
89: 581-584
[Abstract][Full Text]
Yu, F., Venzon, D. J., Serrano, J., Goebel, S. U., Doppman, J. L., Gibril, F., Jensen, R. T.
(1999). Prospective Study of the Clinical Course, Prognostic Factors, Causes of Death, and Survival in Patients With Long-Standing Zollinger-Ellison Syndrome. JCO
17: 615-615
[Abstract][Full Text]
London, J. F., Frucht, H., Doppman, J. L., Maton, P. N., Gardner, J. D., Jensen, R. T.
(1989). Zollinger-Ellison Syndrome in the Intensive Care Setting. J Intensive Care Med
4: 272-283
[Abstract]
